Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: A phase II study
Autore:
Quoix, E; Breton, JL; Daniel, C; Jacoulet, P; Debieuvre, D; Paillot, N; Kessler, R; Moreau, L; Coetmeur, D; Lemarie, E; Milleron, B;
Indirizzi:
Univ Hosp Strasbourg, Pulmonol Unit, F-67091 Strasbourg, France Univ Hosp Strasbourg Strasbourg France F-67091 -67091 Strasbourg, France
Titolo Testata:
ANNALS OF ONCOLOGY
fascicolo: 7, volume: 12, anno: 2001,
pagine: 957 - 962
SICI:
0923-7534(200107)12:7<957:EPWCIT>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
ORAL ETOPOSIDE; CHEMOTHERAPY; INFUSION; AGE; TRIAL; DAY-1;
Keywords:
carboplatin; chemotherapy; comorbidity; elderly; etoposide phosphate; small-cell lung cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Quoix, E Univ Hosp Strasbourg, Pulmonol Unit, 1 Pl Hop, F-67091 Strasbourg, France Univ Hosp Strasbourg 1 Pl Hop Strasbourg France F-67091 , France
Citazione:
E. Quoix et al., "Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: A phase II study", ANN ONCOL, 12(7), 2001, pp. 957-962

Abstract

Background: Although the average age of lung cancer patients is increasing, many elderly patients remain undertreated, mainly because of the fear of higher treatment toxicity in this category of patients. We conducted a study to evaluate the efficacy and tolerability of a combination therapy with carboplatin (C) and etoposide phosphate (EP) in elderly patients with Small-Cell Lung Cancer (SCLC). Patients and methods: Previously untreated patients older than 70 years with stage IIIB/IV SCLC received a combination of EP (100 mg/m(2) D1, D2, D3)and C (D1, dose calculated according to the Calvert formula). Response rate, survival and toxicity were assessed. Results: Thirty-eight patients (mean age 76 years, range 70-88 years) received a total of 162 cycles. Eighteen patients (47%) received the six scheduled cycles. Thirty patients were evaluable for efficacy (2 CR and 20 PR). The median survival was 237 days and the one-year probability of survival was 26%. The most common adverse effect was transient grade 3 or 4 neutropenia, observed during 57% of evaluable cycles, while five episodes of febrile neutropenia also occurred, with one fatal (bactaeriemia). It is noteworthy that no renal or liver toxicity was observed, and no mucitis was noted. Unfortunately, a relatively high proportion of patients died shortly after thestart of the study. Although most deaths seemed unrelated to the treatment, the possibility of its exacerbatory effect on comorbidities, especially cardiovascular, cannot be excluded. Conclusion: The two-drug regimen of carboplatin and etoposide phosphate isfeasible in most elderly patients with an acceptable toxicity, and the overall results suggest that patients even older than 70 years may benefit from full treatment. Therefore, consideration should be given to offering active treatment to most patients with SCLC, regardless of age but with specialattention paid to comorbidities.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 12:50:37